Stock Market

Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and more

In this article

The Mobil logo and gas prices are displayed at a Mobil gas station on October 28, 2022 in Los Angeles, California.
Mario Tama | Getty Images

Check out the companies making headlines in premarket trading.

Plug Power — The battery stock added nearly 6% after the company projected a sharp rise in revenue by 2027 to roughly $6 billion, according to a regulatory filing.

Timken — Shares fell roughly 2% following a downgrade by Bank of America to underperform from neutral, with analyst Michael Feniger noting concern over inventories moving forward.

Take-Two Interactive — Take-Two Interactive Software rose around 1% after Raymond James upgraded the stock to outperform and expressed optimism about its near- and medium-term future. The firm cited a path to more consistent releases and reasonable valuation based on the company’s Grand Theft Auto 6 release soon.

DaVita, Novo Nordisk — Shares of the dialysis services provider sank 15% on the news of Ozempic’s effectiveness in Novo Nordisk’s kidney disease treatment study. Shares of Novo Nordisk added 3.1%.

Exxon Mobil, Pioneer Natural Resources – Shares of Exxon Mobil were lower by more than 1% premarket after the company agreed to buy Pioneer for nearly $60 billion, or $253 per share, in an all-stock merger. Meanwhile, Pioneer shares rose 2.5%. Exxon said production volume in the Permian Basin would more than double after the deal closes.

Humana — Shares dipped slightly after Humana said Bruce Broussard will step down as CEO in the second half of 2024.

Sherwin-Williams — Shares of the paint company fell less than 1% after the Serwin-Williams said Heidi G. Petz would assume the chief executive role beginning Jan. 1, 2024. Petz will also continue in her role as president after assuming CEO duties.

CSX — Shares added nearly 2% after an upgrade to overweight from JPMorgan. The firm said that CSX represents the “best near-term growth opportunity” among U.S. rail stocks.

Amgen — The biotech stock ticked up 0.6% following an upgrade to outperform from Leerink Partners, with analyst David Risinger highlighting long-term revenue potential of $19.3 billion. 

— CNBC’s Tanaya Macheel, Pia Singh and Michelle Fox contributed reporting

Articles You May Like

Anatomy of a deal: JFK New Terminal One’s Northeast winner
Top Wall Street analysts are upbeat on these stocks for the long haul
Young adults in Puerto Rico are struggling financially. Here’s what that means and why some return
Market technicals a boon for muni performance in November
Hawaii plans to price $750 million in GOs in early December